This article was coauthored by Leonardo Vincenzi.

A conventional story about emerging biotech pharma is often one of disadvantage.

Big pharma has budgets, infrastructure and cross-functional global teams. Lean development-stage biotech has science and often the benefit of intense focus. The implicit goal is seen as building a smaller version of large pharma’s commercial machine as the basis for realizing commercial success upon approval. That framing is starting to look outdated.

Conversations with biopharma leaders at recent industry forums, including ZAIDYN® Biopharma Day, point to a different reality taking shape. The most effective emerging companies are not approximating big pharma. They’re operating on a fundamentally different model that is unencumbered by legacy systems and ways of working. Can the emerging biotech and pharma model embrace AI more effectively to produce even better results not just for R&D but also for biotech commercialization?

The shift worth paying attention to is this: lean is no longer being treated as a limitation to manage around. It’s being treated as a design principle to build on.

When constraints shape design

When a commercial operations leader at a large pharma company designs a system, the natural starting point is comprehensiveness: build the dashboard suite; stand up the analytics team; spin up dedicated functions for every adjacent capability. The constraint is not typically resources; rather, it is coordination across resources that already exist.

When the same leader sits down at an emerging biopharma company, the math is different. There may be one person responsible for incentive compensation across brands or distinct indications. The IT team and the commercial operations team may be the same three to five people. The analytics function may not exist as a separate org at all until a much later stage of maturity. Every capability must justify itself against the question: does this directly help us get our medicine or therapy to patients?

That question is clarifying in a way that abundance is not. It forces a hierarchy of needs. It rules out the comfortable middle ground of “nice to have”—except perhaps for the subset of very well-capitalized companies. And it produces an interesting downstream effect: the systems lean teams build, when they build them well, tend to be cleaner, more modular and more honest about what’s actually load-bearing than the systems built by their larger counterparts.

A leader at a company with a recently delayed launch put this directly. Asked what he prioritized when his approval timeline shifted by 15 months, his answer wasn’t about expanding capabilities. It was about understanding how the data was structured, how KPIs were calculated and what was visible underneath the dashboard.

The fancy front end could wait. The foundation had to be right, because everything else depended on the team’s ability to pivot when reality shifted again.

Why lean teams are built for AI

The arrival of agentic AI in life sciences is sometimes pitched as a great equalizer for emerging companies. The narrative usually goes: AI replaces the army of analysts and data scientists that lean teams couldn’t afford, so the playing field levels out. That framing is true but incomplete.

The more precise framing is that agentic AI in life sciences is a force multiplier with an active compounding advantage, given the right foundation. And like every multiplier, what it amplifies depends entirely on what it is pointed at.

AI does not just substitute for headcount. It magnifies whatever foundation it’s deployed against. Pointed at messy data with unclear ownership and ambiguous definitions, it produces messy outputs faster. Pointed at a clean, well-built, well-deployed and well-governed data layer on a platform that serves as a single “source of truth” for key metrics and insights, it produces something genuinely useful.

This is why the lean operating model is, somewhat counterintuitively, well-positioned for the AI era. Not because lean teams have less work to undo but because the discipline that comes from constraint forces decisions about data architecture, ownership and governance earlier and more cleanly.

The companies that have to be intentional about what data products they build and which definitions they commit to end up with the substrate that AI actually needs to be effective.

The opposite pattern emerges at organizations of any size that skip the foundation work and try to layer AI on top. In these cases, technology runs, dashboards populate and agents respond.

But the answers cannot be trusted, because the inputs, processing and automated quality checks were never standardized in the first place. In these cases, AI may expose data deficits and debt, but not pay it down.

The numbers are stark: 67% of life sciences commercial leaders have abandoned an AI initiative specifically because of bad data. Further, Gartner projects that through 2026, organizations will abandon 60% of AI projects unsupported by AI-ready data foundations. These are not technology failures. They are architecture decisions made too late.

What a deliberately lean operation looks like

Across emerging biopharma companies that are getting this right, a common pattern is becoming visible. It’s not a checklist so much as a way of operating.

These organizations treat data as a product, not a byproduct.

Their healthcare provider master, territory definitions and patient-start metrics are treated as deliverables with owners, not simply files that get passed around. They are designed to serve multiple consumers (commercial, medical, market access, vendors) with the same definitions.

And when that data layer is clean and connected, it becomes the substrate for an agentic operating model—one where a central orchestrator agent coordinates domain specialists across field execution, market access, patient support and medical affairs, each operating on the same governed truth and feeding signals back into the system in near-real time.

Successful biopharma companies also invest in foundation before features. The first decision is not which dashboard to build. It’s which platform will the first dashboard, the next dashboard and the dashboard nobody has thought of yet, all draw from. They may also ask if they even need a dashboard if they have the right agent?

This way of operating marks the difference between a company that is minimally launch-ready and a company that is launch-ready and then some and prepared for the second product or indication, or the pivot.

Biopharma companies that are prepared for their future products also prefer modularity over monoliths. The argument for a unified platform is not that it does everything on day one. It’s that it lets you add what you need when you need it, without rebuilding from scratch each time the business changes. Agentic capabilities, omnichannel orchestration, content automation and next best action for field teams including medical all can be deferred until the organization is ready, but the architecture must be capable of accommodating of these known needs and some that may not be foreseeable when that time comes all at once.

And finally, biopharma companies that get it right build responsible AI in from the start, not as an afterthought. In a regulated commercial environment, agentic systems must carry compliance guardrails, auditability and traceability from day one—not retrofitted when a regulatory question arises or a payer pushes back. They treat governance as architecture, not policy.

The opportunity ahead

For emerging biopharma leaders, the structural advantages of building lean and building right have never been more compounding.

The technology has matured. The architecture patterns are proven. And the organizations that commit to the foundation first—data, governance, modular agentic design—are not just better prepared for their first launch. They are building a commercial intelligence engine that pays dividends into every product, indication and market that follows.

Agentic AI, modular platforms and integrated data ecosystems mean capabilities once reserved for organizations with hundreds of analysts are now accessible to teams of three. A company preparing for its first launch in 2026 now can stand up a commercial data foundation with the right architecture discipline in a few months, which until recently would have taken years and required a much larger team to assemble. And because the architecture is modular, that foundation can grow with the company—through a second product, an acquisition, a geographic expansion, a pipeline expansion—without being torn down and rebuilt.

The discipline lean operating requires is also producing leaders who are unusually well-prepared for what is ahead. Operation heads at emerging biotechs are routinely making decisions across IT, commercial, analytics and partner strategy in the same week. That breadth, combined with the clarity that resource constraint forces, is exactly the profile the industry needs more of as AI reshapes how commercial functions operate. The next generation of pharma leadership is being trained right now, in environments where every decision has to count.

The partner ecosystem has matured around this reality, too. Vendors that used to specialize in serving large pharma are building products and engagement models specifically designed for small companies with lean teams—recognizing that the emerging biotech segment is not a stepping stone but a destination market in its own right. That recognition shows up in pricing structures that scale with the business, in implementations measured in weeks rather than years and in advisory and services relationships that look and feel more like partnerships than contracts.

Companies entering the launch window now have something their predecessors did not: a clear operating model that takes their constraints seriously, technology that fits the model and a partner ecosystem aligned to it. The opportunity isn’t to do more with less. It’s to do something different and to do it well and to build something that compounds forward in a moment when the industry has finally caught up to what lean biotech has been building toward all along.

This is the operating model ZAIDYN was built around. It’s modular by design, life sciences-native and engineered to give lean teams the foundation, the platform and the agentic capabilities they need to compete and scale—without the overhead that comes with technology that is not “fit for purpose.”

See how ZAIDYN supports lean biopharma teams—from first launch through every product, indication, geography, portfolio expansion and pivot that follows.